Innoviva Q4 GSK royalties $66M, IST sales up 47% YoY; ZEVTERA launch mid-2025

Innoviva, Inc.

2024-FY EPS reported $0.36 revenue$358,711,000

Q4 GSK royalties $66.0M; full year $255.6M vs $252.7M in 2023.
U.S. net product sales $24.9M in Q4, full year $80.9M (+47% YoY).
Acquired U.S. rights to ZEVTERA; launch expected mid-2025.
Zoliflodacin NDA submission to FDA on track for early 2025.
Cash and receivables $391.4M; net income $20.3M in Q4 ($0.32 EPS).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.